Pure Global
NCT05515562

Effects of Intravenous (IV) Omadacycline on Gut Microbiome

Effects of IV Omadacycline on Gut Microbiome
Wake Forest University Health Sciences·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Microbial Colonization
Drug/Device/Intervention
Omadacycline Injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Wake Forest University Health Sciences
Location
Winston-Salem, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Dec 01, 2022
End date
Dec 01, 2023
Enrollment
8 participants
Primary outcome

Change in gut microbiota concentrations

Summary

Given the clinical need to improve upon current antibiotic regimens for the treatment of C.
 difficile infection with a particular focus on the impact of therapies on gut microbiome,
 this study proposes to characterize the impact of Intravenous (IV) omadacycline on gut
 microbiome of healthy volunteers.

ICD-10 classifications
Bacterial infection of unspecified siteOther bacterial infections of unspecified siteBacterial, viral and other infectious agentsCholeraOther specified bacterial intestinal infections
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05515562
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05515562 through Pure Global AI's free database. This Phase 4 trial is sponsored by Wake Forest University Health Sciences and is currently Not yet recruiting. The study focuses on Microbial Colonization. Target enrollment is 8 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.